130 a, Analyse cytométrique, vol.130, issue.130, p.131 ,
Cinq histoires de leucémie lymphoïde chronique. Hématologie (editorial), pp.2-3, 2006. ,
Quelques éléments d'histoire de l'hématologie biologique, Annales de Biologie Clinique, 2000. ,
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001, Blood, vol.107, issue.1, pp.265-76, 1992. ,
DOI : 10.1182/blood-2005-06-2508
The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect, Blood, vol.116, issue.22, pp.4430-4435, 1986. ,
DOI : 10.1182/blood-2010-05-285221
Chemical exposures and risk of chronic lymphocytic leukaemia, British Journal of Haematology, vol.12, issue.1, pp.753-61, 2007. ,
DOI : 10.1097/00043764-200205000-00015
Evidence for a common genetic aetiology in high-risk families with multiple haematological malignancy subtypes, British Journal of Haematology, vol.109, issue.4, pp.456-62, 2010. ,
DOI : 10.1111/j.1365-2141.2010.08267.x
Familial CLL: Genes and Environment. ASH Education Program Book, pp.339-345, 2007. ,
DOI : 10.1182/asheducation-2007.1.339
URL : http://asheducationbook.hematologylibrary.org/content/2007/1/339.full.pdf
Downregulation of deathassociated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell, pp.879-90, 2007. ,
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia, Nature Genetics, vol.108, issue.10, pp.1204-1214, 2008. ,
DOI : 10.1002/sim.4780040112
Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia. 2010 mars, pp.500-511 ,
Spontaneous clinical regression in chronic lymphocytic leukaemia, British Journal of Haematology, vol.7, issue.2, pp.341-346, 2002. ,
DOI : 10.1007/s002770050113
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, issue.12, pp.5446-5456, 2008. ,
DOI : 10.1182/blood-2007-06-093906
Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia, Leukemia Research, vol.34, issue.7, pp.892-900, 2010. ,
DOI : 10.1016/j.leukres.2010.02.038
Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.27, issue.11, pp.1844-1849, 2009. ,
DOI : 10.1200/JCO.2008.17.0795
B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.360, issue.7, pp.659-67, 2009. ,
DOI : 10.1056/NEJMoa0806122
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL, Leukemia, vol.8, issue.10, pp.1640-1645, 1994. ,
Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b) American journal of clinical pathology, pp.378-82 ,
Expression, Structure, and Function of the CD23 Antigen Advances in Immunology [Internet] Academic Press, pp.149-91, 1991. ,
The role of CD22 and other inhibitory co-receptors in B-cell activation, Current Opinion in Immunology, vol.17, issue.3, pp.290-297, 2005. ,
DOI : 10.1016/j.coi.2005.03.005
Levels of expression of CD19 and CD20 in chronic B cell leukaemias, Journal of Clinical Pathology, vol.51, issue.5, pp.364-373, 1998. ,
DOI : 10.1136/jcp.51.5.364
Diagnostic Significance of CD20 and FMC7 Expression in B-Cell Disorders. AJCP, pp.754-763, 2003. ,
FMC7 is an epitope of CD20, Blood, vol.111, issue.4, pp.2492-2492, 2008. ,
DOI : 10.1182/blood-2007-11-126243
Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia, American Journal of Hematology, vol.40, issue.4, pp.259-63, 1992. ,
DOI : 10.1212/WNL.40.7.1120
The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes, The Journal of Immunology, vol.176, issue.4, pp.2600-2609, 2006. ,
DOI : 10.4049/jimmunol.176.4.2600
Chronic lymphocytic leukemia: a changing natural history?, Leukemia, vol.11, issue.6, pp.775-783, 1997. ,
DOI : 10.1038/sj.leu.2400679
B?chronic lymphocytic leukemia: practical aspects. Hematological Oncology, pp.103-149, 2002. ,
DOI : 10.1002/hon.696
Richter syndrome. Cancer, janv, vol.15103, issue.2, pp.216-244, 2005. ,
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome, British Journal of Haematology, vol.60, issue.3, pp.284-94, 2011. ,
DOI : 10.1016/j.neuron.2008.10.006
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood, pp.3391-3401, 2011. ,
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?, Blood, vol.111, issue.12, pp.5646-5653, 2008. ,
DOI : 10.1182/blood-2008-01-129726
Chronic lymphocytic leukemia and autoimmunity: a systematic review, Haematologica, vol.96, issue.5, pp.752-61, 2011. ,
DOI : 10.3324/haematol.2010.036152
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance, Blood, vol.116, issue.23, pp.4771-4776, 20102. ,
DOI : 10.1182/blood-2010-05-286500
Rituximab???cyclophosphamide???dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.95, issue.7, pp.1401-1404, 2011. ,
DOI : 10.1002/ajh.20665
Infectious complications of chronic lymphocytic leukemia. Seminars in oncology, pp.240-249, 2006. ,
Infectious complications in chronic lymphocytic leukaemia. Hematology and Cell Therapy, pp.145-51, 1999. ,
Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine. Annals of Internal Medicine, pp.559-566, 1998. ,
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent, Blood, vol.81, issue.11, pp.2878-84, 1993. ,
Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study, Haematologica, vol.81, issue.2, pp.121-126, 1996. ,
Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes, British Journal of Haematology, vol.3, issue.1, pp.209-221, 1994. ,
DOI : 10.1001/archinte.132.4.562
Vaccination Against Infections in Chronic Lymphocytic Leukemia, Leukemia & Lymphoma, vol.48, issue.7, pp.649-52, 2003. ,
DOI : 10.1046/j.1365-2249.2000.01109.x
Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine, pp.13-141671, 2001. ,
Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia, British Journal of Haematology, vol.106, issue.1, pp.107-117, 2001. ,
DOI : 10.1001/archinte.1960.03820040005002
Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011, Journal of Clinical Oncology, vol.19, issue.16, pp.3611-3632, 2001. ,
DOI : 10.1200/JCO.2001.19.16.3611
Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab, Clinical Lymphoma and Myeloma, vol.7, issue.2, pp.125-155, 2006. ,
DOI : 10.3816/CLM.2006.n.049
Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Journal of Clinical Oncology, vol.27, issue.6, pp.904-910, 2009. ,
DOI : 10.1200/JCO.2008.17.5398
Second Cancers in patients With Chronic Lymphocytic Leukemia, JNCI Journal of the National Cancer Institute, vol.84, issue.18, pp.1422-1427, 1992. ,
DOI : 10.1093/jnci/84.18.1422
Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism, Journal of the National Cancer Institute, vol.61, issue.2, p.337 ,
Advances in the Clinical Staging of Chronic Lymphocytic Leukemia, Clinical Chemistry, vol.57, issue.12, pp.219-234, 1975. ,
DOI : 10.1373/clinchem.2010.159004
Chronic Lymphocytic Leukaemia: Proposals for a Revised Prognostic Staging System., British Journal of Haematology, vol.65, issue.3, pp.365-372, 1981. ,
DOI : 10.1002/1097-0142(197808)42:2+<941::AID-CNCR2820420717>3.0.CO;2-1
Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone, Cancer, vol.2, issue.10, pp.2369-75, 1985. ,
DOI : 10.1016/0360-3016(79)90736-3
Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters, Blood, vol.116, issue.22, pp.4588-4590, 2010. ,
DOI : 10.1182/blood-2010-06-288274
Chronic Lymphocytic Leukemia: Diagnosis and Treatment, Mayo Clinic Proceedings, vol.81, issue.8, pp.1105-1134, 2006. ,
DOI : 10.4065/81.8.1105
Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance, British Journal of Haematology, vol.6, issue.3, pp.567-75, 1986. ,
DOI : 10.1016/0002-9343(69)90242-3
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells, Journal of Clinical Investigation, vol.115, issue.3, pp.755-64, 2005. ,
DOI : 10.1172/JCI23409DS1
The serum beta2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia, Blood, vol.86, issue.1, p.606, 1995. ,
Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and ??2-microglobulin in B-cell chronic lymphocytic leukemia, European Journal of Haematology, vol.92, issue.suppl 1, pp.117-139, 1999. ,
DOI : 10.1111/j.1600-0609.1980.tb02364.x
Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer, pp.2450-2455, 1984. ,
Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia, Blood, vol.93, issue.5, pp.1732-1739, 1999. ,
Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia, Blood, vol.88, issue.11, pp.4259-64, 1996. ,
Prognostic relevance of soluble CD23 levels in CLL, The Hematology Journal, vol.2, issue.5, pp.355-355, 2001. ,
DOI : 10.1038/sj.thj.6200129
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia, Blood, vol.94, issue.6, pp.1840-1847, 1999. ,
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia, Blood, vol.94, issue.6, pp.1848-1854, 1999. ,
Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood, juill, vol.15106, issue.2, pp.681-690, 2005. ,
Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood, mars, vol.1599, issue.6, pp.2262-2264, 2002. ,
Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells, The Journal of Experimental Medicine, vol.94, issue.11, pp.1625-1663, 2001. ,
DOI : 10.1038/ng0193-88
Zap 70, Cell. nov, vol.1371, issue.4, pp.649-62, 1992. ,
DOI : 10.1016/B978-012324719-3/50160-6
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia, The Journal of Experimental Medicine, vol.8, issue.11, pp.1639-1648, 2001. ,
DOI : 10.1006/geno.1996.0177
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood, pp.4609-4614, 2002. ,
ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.348, issue.18, pp.1764-75, 2003. ,
DOI : 10.1056/NEJMoa023143
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. The Lancet, pp.105-116, 2004. ,
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.351, issue.9, pp.893-901, 2004. ,
DOI : 10.1056/NEJMoa040857
More ZAP for chronic lymphocytic leukemia (CLL). Blood, mars, vol.1105, issue.5, pp.1839-1879, 2005. ,
DOI : 10.1182/blood-2004-12-4758
URL : http://www.bloodjournal.org/content/bloodjournal/105/5/1839.full.pdf
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells, Blood, vol.102, issue.6, pp.2146-2155, 2003. ,
DOI : 10.1182/blood-2003-03-0989
Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression, The Journal of Immunology, vol.157, issue.4, pp.1455-1467, 1996. ,
The CD38 molecule, antigen and ecto-enzyme: for which function?, Hématologie, vol.6, issue.1, pp.24-33, 2000. ,
CD38 in T-and B-cell functions. Human CD38 and related molecules, pp.146-68, 2000. ,
Clinical significance of CD38 expression in chronic lymphocytic leukemia, Blood, vol.98, issue.9, pp.2633-2642, 2001. ,
DOI : 10.1182/blood.V98.9.2633
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia, Leukemia, vol.16, issue.1, pp.30-35, 2002. ,
DOI : 10.1038/sj.leu.2402339
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia, Blood, vol.98, issue.1, pp.181-186, 2001. ,
DOI : 10.1182/blood.V98.1.181
Chromosome aberrations in B-cell chronic lymphocytic leukemia, Cancer Genetics and Cytogenetics, vol.45, issue.2, pp.143-60, 1990. ,
DOI : 10.1016/0165-4608(90)90079-P
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.26, pp.1910-1916, 2000. ,
DOI : 10.1056/NEJM200012283432602
Anomalies g??n??tiques des leuc??mies lymphoides chroniques, Pathologie Biologie, vol.51, issue.6, pp.366-74 ,
DOI : 10.1016/S0369-8114(03)00083-X
New insights into the pathogenesis of chronic lymphocytic leukemia. Seminars in Cancer Biology, pp.377-83, 2010. ,
Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients, British Journal of Haematology, vol.92, issue.2, pp.382-390, 1996. ,
DOI : 10.1046/j.1365-2141.1996.d01-1478.x
11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis, Blood, vol.89, issue.7, pp.2516-2538, 1997. ,
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias, Blood. mars, vol.1585, issue.6, pp.1580-1589, 1995. ,
Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial, Journal of Clinical Oncology, vol.29, issue.16, pp.2223-2232, 2011. ,
DOI : 10.1200/JCO.2010.32.0838
Mutation and Survival in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.28, issue.29, pp.4473-4482, 2010. ,
DOI : 10.1200/JCO.2009.27.8762
Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia, Leukemia, vol.13, issue.9, pp.1331-1335 ,
hTERT expression and prognosis in B-chronic lymphocytic leukemia. Annals of Oncology, pp.1476-1480, 2004. ,
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia, Blood, vol.108, issue.3, pp.1001-1006, 2006. ,
DOI : 10.1182/blood-2005-05-2110
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia, Leukemia Research, vol.31, issue.11, pp.1575-1583, 2007. ,
DOI : 10.1016/j.leukres.2007.03.009
A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.353, issue.17, pp.1793-801, 2005. ,
DOI : 10.1056/NEJMoa050995
intérêt pronostique et mécanismes moléculaires de l'expression de MCL-1, IL-6 et VEGF dans la leucémie lymphoïde chronique [Internet]. [Clermont-Ferrand 1]: Clermont-Ferrand, 2007. ,
Les hémopathies lymphoïdes chroniques de l'adulte: la leucémie lymphoïde chronique et la phase de dissémination des lymphomes à petites cellules, Annales de Biologie Clinique, 2001. ,
Association of B?chronic lymphocytic leukaemia and T?large granular lymphocyte leukaemia. Clinical & Laboratory Haematology, pp.121-123, 20089. ,
Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia, Leukemia & Lymphoma, vol.72, issue.5, pp.932-940 ,
DOI : 10.7326/0003-4819-146-9-200705010-00009
Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients, Blood, issue.7, pp.751414-751435 ,
Chlorambucil in Indolent Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.338, issue.21, pp.1506-1520, 1998. ,
DOI : 10.1056/NEJM199805213382104
Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematological Oncology, pp.7-12, 1988. ,
Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents, Clinical Cancer Research, vol.14, issue.1, pp.309-326, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1061
Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL) : results of an international phase III study [Internet], 2007. ,
Bendamustine in Combinaison with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [Internet], 2007. ,
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, pp.19-25, 1989. ,
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.24, pp.1750-1757, 2000. ,
DOI : 10.1056/NEJM200012143432402
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients, Blood, vol.98, issue.8, pp.2319-2344, 2001. ,
DOI : 10.1182/blood.V98.8.2319
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia, Blood, vol.107, issue.3, pp.885-891, 2006. ,
DOI : 10.1182/blood-2005-06-2395
Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.19, issue.5, pp.1414-1420, 2001. ,
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells, Leukemia, vol.91, issue.9, pp.1580-1587, 2010. ,
DOI : 10.4049/jimmunol.164.4.2200
THE USE OF ???CHOP??? IN THE TREATMENT OF CLL, British Journal of Haematology, vol.73, issue.4, pp.546-546, 1990. ,
DOI : 10.1111/j.1365-2141.1990.tb06353.x
CHOP Versus Chlorambucil + Prednisolone in Chronic Lymphocytic Leukemia, Leukemia & Lymphoma, vol.30, issue.sup1, pp.97-100, 1991. ,
DOI : 10.1111/j.1600-0609.1981.tb00485.x
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study, Blood, vol.99, issue.10, pp.3554-3561, 2002. ,
DOI : 10.1182/blood.V99.10.3554
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer, pp.2657-63, 2003. ,
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL), Blood, vol.100, issue.3, pp.768-773, 2002. ,
DOI : 10.1182/blood-2002-01-0159
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.25, issue.35, pp.5616-5639, 2007. ,
DOI : 10.1200/JCO.2007.12.9098
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia, Blood, vol.98, issue.5, pp.1326-1331, 2001. ,
DOI : 10.1182/blood.V98.5.1326
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011, Blood, vol.105, issue.1, pp.49-53, 2005. ,
DOI : 10.1182/blood-2004-03-0796
First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) versus fludarabine and cyclophosphamide (FC) improves overall survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL), Blood, vol.114, p.22, 2009. ,
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.23, issue.18, pp.4079-4088, 2005. ,
DOI : 10.1200/JCO.2005.12.051
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8). Blood, pp.2217-2224, 1999. ,
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.28, issue.10, pp.1749-55, 2010. ,
DOI : 10.1200/JCO.2009.25.3187
884 Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia, 2009. ,
Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated patients-first results from a phase II study in patients with relapsed/refractory indolent NHL (INHL), Haematologica, vol.95, p.229, 2010. ,
Allotransplants and autotransplants in CLL, Bone Marrow Transplant, vol.23, issue.1, p.53, 1999. ,
The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status, Blood, vol.103, issue.7, pp.2850-2858, 2004. ,
DOI : 10.1182/blood-2003-05-1549
Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial, Bone Marrow Transplantation, vol.112, issue.4, pp.542-550, 2011. ,
DOI : 10.1182/blood-2008-02-140582
URL : https://hal.archives-ouvertes.fr/inserm-00821100
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation, Blood, vol.117, issue.5, pp.1516-1537, 20112. ,
DOI : 10.1182/blood-2010-09-308775
Stem cell transplantation for chronic lymphocytic leukaemia, British Journal of Haematology, vol.25, issue.1, pp.145-52, 2005. ,
DOI : 10.1038/sj.leu.2401201
HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia, Annals of Internal Medicine, vol.124, issue.3 ,
DOI : 10.7326/0003-4819-124-3-199602010-00005
Reducedintensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia, pp.1029-1062, 2005. ,
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus, Leukemia, vol.23, issue.1, pp.12-19, 2006. ,
DOI : 10.1200/JCO.2005.04.531
Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.23, issue.30, pp.7697-702, 2005. ,
DOI : 10.1200/JCO.2005.02.4364
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.110, issue.1, pp.27-38, 2010. ,
DOI : 10.1111/j.1365-2141.2008.07548.x
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.29, issue.9, pp.1175-81, 2011. ,
DOI : 10.1200/JCO.2010.29.8133
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study, Journal of Clinical Oncology, vol.24, issue.34, pp.5343-5349, 2006. ,
DOI : 10.1200/JCO.2005.05.0401
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood, pp.3489-98, 2011. ,
Toward chemotherapy-free treatment of CLL, Blood, vol.118, issue.13, pp.3451-3452, 2011. ,
DOI : 10.1182/blood-2011-08-367748
Chimeric Antigen Receptor???Modified T Cells in Chronic Lymphoid Leukemia, New England Journal of Medicine, vol.365, issue.8, pp.725-758, 2011. ,
DOI : 10.1056/NEJMoa1103849
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia, Blood, vol.113, issue.12, pp.2637-2682 ,
DOI : 10.1182/blood-2008-07-168583
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach, Haematologica, vol.97, issue.3, pp.423-430 ,
DOI : 10.3324/haematol.2011.047324
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood, pp.1492-1500, 2011. ,
Chronic lymphocytic leukaemia responsive to vitamin D administration, British Journal of Haematology, vol.117, issue.1, pp.148-157 ,
DOI : 10.1182/blood-2010-07-295683
Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial, Journal of Clinical Oncology, vol.30, issue.9, pp.980-988 ,
DOI : 10.1200/JCO.2011.36.9348
B-Cell Chronic Lymphocytic Leukemia: A Bird of a Different Feather, Journal of Clinical Oncology, vol.17, issue.1, p.399, 1999. ,
DOI : 10.1200/JCO.1999.17.1.399
Role of the microenvironment in chronic lymphocytic leukaemia, British Journal of Haematology, vol.95, issue.3, pp.380-388, 2003. ,
DOI : 10.1038/sj.leu.2401602
Mechanisms of B-cell lymphoma pathogenesis, Nature Reviews Cancer, vol.2, issue.4, pp.251-62 ,
DOI : 10.1038/nrc746
: Lessons Learned from Studies of the B Cell Antigen Receptor, Annual Review of Immunology, vol.21, issue.1, pp.841-94, 2003. ,
DOI : 10.1146/annurev.immunol.21.120601.141018
Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity, Journal of Clinical Investigation, vol.115, issue.6, pp.1636-1679, 2005. ,
DOI : 10.1172/JCI24387DS1
Circulating Human B Cells That Express Surrogate Light Chains Display a Unique Antibody Repertoire, The Journal of Immunology, vol.167, issue.4, pp.2151-2157, 2001. ,
DOI : 10.4049/jimmunol.167.4.2151
Mutation Status, Journal of Clinical Oncology, vol.22, issue.19, pp.3937-3986, 2004. ,
DOI : 10.1200/JCO.2004.12.133
Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.352, issue.8, pp.804-819, 2005. ,
DOI : 10.1056/NEJMra041720
URL : https://hal.archives-ouvertes.fr/hal-01375537
Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone, Blood, vol.102, issue.9, pp.3333-3342, 2003. ,
DOI : 10.1182/blood-2003-05-1585
Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia, Immunology, vol.11, issue.4, pp.441-450, 2005. ,
DOI : 10.1182/blood.V97.9.2777
Regulation of B-CLL Apoptosis Through Membrane Receptors and Bcl-2 Family Proteins, Leukemia & Lymphoma, vol.154, issue.3-4, pp.3-4247, 1998. ,
DOI : 10.1002/eji.1830240532
bcl-2 gene hypomethylation and highlevel expression in B-cell chronic lymphocytic leukemia, Blood, vol.82, issue.6, pp.1820-1828, 1993. ,
Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance, British Journal of Cancer, vol.76, issue.7, pp.935-943, 1997. ,
DOI : 10.1038/bjc.1997.487
MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia, pp.444-54, 2002. ,
Prognostic Significance of a Short Sequence Insertion in the MCL-1 Promoter in Chronic Lymphocytic Leukemia, JNCI Journal of the National Cancer Institute, vol.266, issue.27, pp.673-82, 2004. ,
DOI : 10.1038/358331a0
Prognostic Significance of the Cell Cycle Inhibitor p27Kip1 in Chronic B-Cell Lymphocytic Leukemia, Blood, vol.91, issue.12, pp.4694-4700, 1998. ,
Adhesion to Bone Marrow Stroma Inhibits Apoptosis of Chronic Lymphocytic Leukemia Cells, Leukemia & Lymphoma, vol.152, issue.5-6, pp.5-6445, 1999. ,
DOI : 10.1006/cimm.1998.1360
Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells, Blood, vol.94, issue.11, pp.3658-3667, 1999. ,
The levels of TNF?, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL). Leukemia Research, pp.157-63, 2001. ,
Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen, Journal of Experimental Medicine, vol.141, issue.6, pp.1376-89, 1975. ,
DOI : 10.1084/jem.141.6.1376
T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views, Journal of Experimental Medicine, vol.152, issue.2, pp.280-95, 1980. ,
DOI : 10.1084/jem.152.2.280
Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies., Proceedings of the National Academy of Sciences, pp.2494-2498, 1984. ,
DOI : 10.1073/pnas.81.8.2494
URL : http://www.pnas.org/content/81/8/2494.full.pdf
Expression of Lyt-1 by a subset of B lymphocytes, J Immunol, vol.129, issue.2, pp.532-540, 1982. ,
Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells, European Journal of Immunology, vol.39, issue.12, pp.900-904, 1978. ,
DOI : 10.1002/eji.1830081214
Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia, Journal of Experimental Medicine, vol.155, issue.2, pp.623-631, 1982. ,
DOI : 10.1084/jem.155.2.623
Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. , Published online, pp.346-355, 1986. ,
An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors., Proceedings of the National Academy of Sciences, vol.87, issue.22, pp.8810-8814, 1990. ,
DOI : 10.1073/pnas.87.22.8810
Structural analysis of the CD5 antigen. Expression, disulphide bond analysis and physical characterisation of CD5 scavenger receptor superfamily domain 1, European Journal of Biochemistry, vol.257, issue.1, pp.131-172, 1998. ,
DOI : 10.1046/j.1432-1327.1998.2570131.x
CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and protein-tyrosine kinases p56lck and p59fyn., Proceedings of the National Academy of Sciences, vol.89, issue.19, pp.9311-9316, 1992. ,
DOI : 10.1073/pnas.89.19.9311
CD5 is phosphorylated on tyrosine after stimulation of the T-cell antigen receptor complex., Proceedings of the National Academy of Sciences, vol.89, issue.14, pp.6368-72, 1992. ,
DOI : 10.1073/pnas.89.14.6368
In vivo association of CD5 with tyrosine-phosphorylated ZAP-70 and p21 phospho-zeta molecules in human CD3+ thymocytes. The Journal of Immunology, oct, vol.15159, issue.8, pp.3739-3747, 1997. ,
Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5, European Journal of Immunology, vol.156, issue.3, pp.679-86, 1997. ,
DOI : 10.1128/MCB.15.6.3049
Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase, Journal of Experimental Medicine, vol.184, issue.3, pp.839-52, 1996. ,
DOI : 10.1084/jem.184.3.839
Negative regulation of antigen receptor-mediated signaling by constitutive asociation of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells, European Journal of Immunology, vol.147, issue.10, pp.3319-3347, 1999. ,
DOI : 10.1128/MCB.19.4.2903
CD5 Negatively Regulates the T-Cell Antigen Receptor Signal Transduction Pathway: Involvement of SH2-Containing Phosphotyrosine Phosphatase SHP-1, Molecular and Cellular Biology, vol.19, issue.4, pp.2903-2915, 1999. ,
DOI : 10.1128/MCB.19.4.2903
The Pseudo-immunoreceptor Tyrosine-based Activation Motif of CD5 Mediates Its Inhibitory Action on B-cell Receptor Signaling, Journal of Biological Chemistry, vol.162, issue.1, pp.548-56, 2000. ,
DOI : 10.1084/jem.182.2.611
CD5 expression in human B-cell populations. Immunology Today, pp.312-318, 1999. ,
The human fetal omentum: a site of B cell generation, Journal of Experimental Medicine, vol.175, issue.2, pp.397-404, 1992. ,
DOI : 10.1084/jem.175.2.397
Development and Physiology of LY?1 B and its Human Homolog, LEU?1 B. Immunological Reviews, pp.53-80, 1986. ,
CD5-positive B cells in rheumatoid arthritis and chronic lymphocytic leukemia, Immunology Today, vol.8, issue.2, pp.37-46, 1987. ,
DOI : 10.1016/0167-5699(87)90235-0
Human peritoneal B-1 cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels, Clinical and Experimental Immunology, vol.109, issue.2, pp.356-61, 1997. ,
DOI : 10.1046/j.1365-2249.1997.4541352.x
Age-related changes in human blood lymphocyte subpopulations, The Journal of Pediatrics, vol.120, issue.2, pp.216-238, 1992. ,
DOI : 10.1016/S0022-3476(05)80430-5
CD5: A safeguard against autoimmunity and a shield for cancer cells, Autoimmunity Reviews, vol.8, issue.4, pp.349-53, 2009. ,
New Insights into the Phenotype and Cell Derivation of B Cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, pp.31-49, 2005. ,
DOI : 10.1007/3-540-29933-5_3
A rheumatoid arthritis b cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis & Rheumatism, pp.971-977, 1985. ,
Rheumatoid factor secretion from human Leu-1+ B cells. Science, pp.81-84, 1987. ,
Cd5 Maintains Tolerance in Anergic B Cells, The Journal of Experimental Medicine, vol.36, issue.5, pp.883-90 ,
DOI : 10.1111/j.1749-6632.1992.tb24661.x
Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies, Journal of Autoimmunity, vol.1, issue.5, pp.469-81, 1988. ,
DOI : 10.1016/0896-8411(88)90068-6
CD5 is associated with the human B cell antigen receptor complex, European Journal of Immunology, vol.136, issue.4, pp.812-818, 1994. ,
DOI : 10.1002/eji.1830240406
CD5-Mediated Negative Regulation of Antigen Receptor-Induced Growth Signals in B-1 B Cells, Science, vol.274, issue.5294, pp.1906-1909, 1996. ,
DOI : 10.1126/science.274.5294.1906
SHP-1 Requires Inhibitory Co-receptors to Down-modulate B Cell Antigen Receptor-mediated Phosphorylation of Cellular Substrates, Journal of Biological Chemistry, vol.16, issue.28, pp.26648-26655, 2001. ,
DOI : 10.1002/(SICI)1521-4141(199910)29:10<3319::AID-IMMU3319>3.0.CO;2-9
Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends in Immunology, pp.543-50, 2004. ,
Lyn Tyrosine Kinase, Immunity, vol.22, issue.1, pp.9-18, 2005. ,
DOI : 10.1016/j.immuni.2004.12.004
Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases, Blood, vol.81, issue.10, p.2475, 1993. ,
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma study group, Current Diagnostic Pathology, vol.2, issue.1, pp.1361-92, 1994. ,
DOI : 10.1016/S0968-6053(00)80051-4
Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor, J Immunol déc, vol.15151, issue.12, pp.7273-83, 1993. ,
Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis, Journal of Clinical Investigation, vol.115, issue.2, pp.369-78, 2005. ,
DOI : 10.1172/JCI200522094
Modulation of apoptosis by cytokines in B?cell chronic lymphocytic leukemia, Cytometry oct, vol.1538, issue.5, pp.224-254, 1999. ,
Biological properties of interleukin 10, Journal of Clinical Immunology, vol.25, issue.4, pp.239-286, 1992. ,
DOI : 10.1146/annurev.iy.06.040188.001213
Human CD5 Promotes B-Cell Survival Through Stimulation of Autocrine IL-10 Production. Blood, pp.4537-4580, 2002. ,
Growth-and Differentiation-Associated Expression of Bcl-2 in B-Chronic Lymphocytic Leukemia Cells, Blood, vol.79, issue.11, pp.2981-2990, 1992. ,
CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia, Leukemia, vol.16, issue.1, pp.44-52, 2002. ,
DOI : 10.1038/sj.leu.2402327
Chronic Lymphocytic Leukemia in Young Adults: Report of Six Cases Under the Age of 30 Years, Leukemia & Lymphoma, vol.4, issue.sup1, pp.179-82, 1991. ,
DOI : 10.1016/S0022-3476(05)81658-0
Presenting Features and Prognosis of Chronic Lymphocytic Leukemia in Younger Adults [see Comments]. Blood, pp.1545-51, 1991. ,
Comparison of the (A, B, C) staging and the Rai's staging from a large prospective series (935 patients) Nouvelle Revue Française d'Hématologie, pp.363-370, 1988. ,
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease, Blood, vol.99, issue.3, pp.1023-1032, 20022. ,
DOI : 10.1182/blood.V99.3.1023